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vessel density and invasion through image
analysis in colorectal cancer
Peter D Caie1,2*, Arran K Turnbull1,2, Susan M Farrington2, Anca Oniscu1,3 and David J Harrison1,3Abstract
Background: Tumour budding (TB), lymphatic vessel density (LVD) and lymphatic vessel invasion (LVI) have shown
promise as prognostic factors in colorectal cancer (CRC) but reproducibility using conventional histopathology is
challenging. We demonstrate image analysis methodology to quantify the histopathological features which could
permit standardisation across institutes and aid risk stratification of Dukes B patients.
Methods: Multiplexed immunofluorescence of pan-cytokeratin, D2-40 and DAPI identified epithelium, lymphatic
vessels and all nuclei respectively in tissue sections from 50 patients diagnosed with Dukes A (n = 13), Dukes B
(n = 29) and Dukes C (n = 8) CRC. An image analysis algorithm was developed and performed, on digitised images
of the CRC tissue sections, to quantify TB, LVD, and LVI at the invasive front.
Results: TB (HR =5.7; 95% CI, 2.38-13.8), LVD (HR =5.1; 95% CI, 2.04-12.99) and LVI (HR =9.9; 95% CI, 3.57-27.98) were
successfully quantified through image analysis and all were shown to be significantly associated with poor survival,
in univariate analyses. LVI (HR =6.08; 95% CI, 1.17-31.41) is an independent prognostic factor within the study and
was correlated to both TB (Pearson r =0.71, p <0.0003) and LVD (Pearson r =0.69, p <0.0003).
Conclusion: We demonstrate methodology through image analysis which can standardise the quantification of TB,
LVD and LVI from a single tissue section while decreasing observer variability. We suggest this technology is
capable of stratifying a high risk Dukes B CRC subpopulation and we show the three histopathological features to
be of prognostic significance.
Keywords: Image analysis, Lymphatic vessel density, Lymphatic vessel invasion, Tumour budding, Colorectal,
Prognosis, Digital pathologyBackground
Although there exist subtypes of colorectal cancer (CRC),
defined by disrupted molecular pathways, in clinical prac-
tice prognosis and recommendation for adjuvant therapy
relies upon histopathological analysis of haematoxylin and
eosin (H&E) stained tissue sections and the consequent
TNM or Dukes staging of the tumour [1,2]. Surgical re-
section is undertaken as a curative procedure for Dukes
A and B patients [3]. However, there is a subgroup, of 5
and 20-30% of patients respectively, who relapse and* Correspondence: p.d.caie@sms.ed.ac.uk
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reproduction in any medium, provided the or
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unless otherwise stated.experience poor 5 year survival rates [4]. It is therefore
imperative to successfully identify those patients who
are at high risk of disease recurrence and who may have
been under-staged.
A wealth of original studies, systematic and meta-
analysis reviews have been published on the subject of
lymphatic vessel invasion (LVI) [5-7], lymphatic vessel
density (LVD) [8-10] and tumour budding (TB) [11-15]
in CRC prognosis [16,17]. A number of these have con-
centrated on early stage disease and the ability to utilise
histopathological features to predict lymph node metas-
tasis or to stratify patients at high risk of disease recur-
rence and poor outcome [6,9,16,18-22]. Although LVI and
TB have been shown to be significantly prognostic in most
of these studies they are not, along with LVD, routinely. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cluded within the minimum core data set compiled by the
Royal College of Pathologists [1], wherein only TB is
listed as a non-core data item. There are a number of
reasons for this; inter-observer variability [7,9,23,24],
multiple quantification methodologies resulting in no
agreed or standardised reporting system [12,14,15,25]
and the difficulty in observing occult phenomena in
routine H&E stained tissue sections [26-28]. In fact
lymphatic vessels, unlike blood vessels, are especially
difficult to observe in H&E stained tissue sections where
they may be confused with retraction artefact. Specific
stains are more frequently being employed [9,22,26,28-30]
in order to increase reporting rate and decrease observer
variability but there is no consensus yet on what is best.
Thus the manual, semi-quantitative scoring employed in
these studies is subjective, open to variability and time
consuming.
The field of digital pathology is gaining momentum
and beginning to be incorporated into routine clinical
practice with regulatory clearance for primary diagnosis,
for example, most recently approved in Canada [31]. Sev-
eral studies incorporate image analysis, for example the
quantification of immune infiltrate in the CRC micro-
environment [32,33], and demonstrate the advantages this
methodology could bring to the clinic. Automated image
analysis of pathological slides, with its attributes of robust
high throughput, fully quantitative and continuous data
sets, however still remains largely in the realm of research.
Here we demonstrate methodology for the computer
based quantification of LVI, LVD and TB at the invasive
front of CRC tissue sections that could, if validated, be
applied in clinical practice. The study utilises multi-
plexed immunofluorescence coupled with a novel image
analysis algorithm to quantify the three histopathological
features from a single tissue section. This approach allows
implementation of standardised, high throughput quantifi-
cation which could be used consistently in different insti-
tutes while minimising observer variability. We investigate
if the quantification of the three histopathological features
allows the stratification of Dukes B patients into high and
low risk of poor outcome. Additionally we assess the
potential for the methodology to further stratify patients
with Dukes A to C CRC, into more precisely defined
high and low risk subgroups.
Methods
Patients and specimens
50 patients were selected from a prospectively collected,
pan-Scotland CRC cohort of patients under the age of
60 for whole slide imaging (WSI). Dukes B patients were
selected on outcome (n = 29; 16 survived follow up and
13 died of CRC during follow up) in order to assess the
ability of the methodology to successfully stratify thesubgroup as high or low risk of disease specific survival.
Dukes A (n = 13) and Dukes C (n = 8) patients were ran-
domly selected for this study from the pan-Scotland co-
hort. Patients underwent surgical resection between the
years of 1996 and 2003. Tumours located from the Cae-
cum to transverse colon were amalgamated into right-
sided CRC (n = 17), tumours left of the splenic flexure to
the sigmoid colon were defined as left-sided CRC (n =
16) and tumours from within the recto-sigmoid and rec-
tum were defined as rectal CRC (n = 17). A total of 40%
of the patients died specifically from CRC within the pa-
tient follow up which was up to 15 years. Clinicopatho-
logical characteristics are summarised in Table 1.
The tissue used in this project was residual diagnostic
material stored in the NHS Lothian diagnostic archive
and provided by the NHS Lothian NRS BioResource.
The provison of this material and the subsequent re-
search was conducted under the approval held the NHS
Lothian NRS BioResource, which is a REC-approved
Research Tissue Bank (REC approval ref: 13/ES/0126).
This approval was granted by East of Scotland Research
Ethics Service, which is part of the National Research
Ethics service and NHS Health Research Authority.
This provides the necessary ethical approval for the
BioResource, and associated researchers to collect, store
and use patient samples and associated clinical data for re-
search. In accordance with the approval held, all samples
were anonymised when released by the BioResource to
the research group.
Each patient was interviewed and signed informed
consent was obtained for partaking in research.
Immunofluorescence
FFPE tissue blocks were sectioned at 4 μm, dewaxed and
rehydrated in preparation for immunofluorescence. Pres-
sure cooker heat-induced antigen retrieval was performed
with Tris-EDTA, pH9 buffer. Endogenous hydrogen per-
oxidase was blocked with 3% hydrogen peroxide solution.
Sections were incubated in DAKO serum-free block
(DAKO, X0909) to reduce non-specific binding of anti-
bodies. Next, sections were incubated for 1 hour at room
temperature with primary mouse antibody against D2-40
(Dako, M3619, 1:2000) prior to an overnight 4˚C incuba-
tion of primary rabbit antibody against wide spectrum
cytokeratin (Dako, Z0622, 1:150). Both antibodies were
diluted in Dako antibody diluent (Dako, S0809). Dual
antibody visualisation was performed by incubating slides
in a secondary antibody solution of goat anti-rabbit
Alexa555 conjugated antibody (Invitrogen, A21428, 1:25)
and Dako Envision goat-mouse HRP antibody (Dako,
K4001) for 1.5 hours in the dark at room temperature.
Cy5 Tyramide (Perkin Elmer, SAT705A001EA, 1:100)
was used to incubate the tissue for 10 minutes at room
temperature for HRP signal amplification. Finally nuclei
Table 1 Clinicopathological data with univariate and multivariable analysis for disease specific survival within the CRC
cohort
Clinicopathological
parameters
Patient
number (n)
Univariate Multivariable
HR 95% CI P value HR 95% CI P value
Lower Upper Lower Upper
Dukes 3.34 1.61 7.01 0.001 0.33 0.08 1.36 0.12
A 13
B 29
C 8
Gender 1.77 0.73 4.31 0.26 N/A
M 24
F 26
Age at diagnosis 0.99 0.92 1.05 0.773 N/A
30s 5
40s 27
50s 18
T stage 3.04 1.53 6.03 0.001 5.22 1.77 15.44 0.03
pT1 7
PT2 7
pT3 27
pT4 9
N Stage 2.62 1.54 4.46 <0.001 1.62 0.69 3.81 0.27
N0 40
N1 8
N2 1
N3 1
Differentiation 1.14 0.37 3.54 0.83 N/A
Well 5
Moderate 39
Poor 6
Histology 0.49 0.11 2.11 0.34 N/A
Standard 42
Mucinous 8
Site 0.77 0.45 1.31 0.33 N/A
Rectal 17
Right side 17
Left side 16
Budding 5.76 2.38 13.8 0.0005 2.56 0.9 7.27 0.08
High 13
Medium 19
Low 18
LVI 9.99 3.57 27.98 0.0001 6.08 1.17 31.41 0.03
High 13
Medium 19
Low 18
Caie et al. Journal of Translational Medicine 2014, 12:156 Page 3 of 12
http://www.translational-medicine.com/content/12/1/156
Table 1 Clinicopathological data with univariate and multivariable analysis for disease specific survival within the CRC
cohort (Continued)
LVD 5.15 2.04 12.99 0.00001 1.3 0.3 5.59 0.72
High 18
Medium 11
Low 21
N/A indicates that the parameter was not included for multivariable analysis due to insignificance in univariate analysis. A parameter with a hazard ratio (HR) of
greater than one has an adverse effect on survival and a p value of less than 0.05 was considered significant (bold type).
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mounted by adding Prolong Gold anti-fade reagent con-
taining DAPI (Invitrogen, P36931) to a coverslip.
Image analysis
Low resolution WSI was performed at 4x objective using
an Olympus AX-51 epifluorescence microscope (Olympus,
Pennsylvania, USA). The invasive front of each tissue sec-
tion was visually established from the low resolution image
and then captured through a series of 20x objective im-
ages. Post capture the monochromatic high definition
image layers for the panCK (epithelium), D2-40 (lymphatic
vessel) and DAPI (nuclei) channels were imported into
Definiens image analysis software (Definiens AG, Munich)
for image segmentation and classification of TB, LVI
and LVD. Images were automatically segmented into the
regions of interest (ROIs); Tumour, Stroma, Necrosis/
Lumen and No tissue, after a previous supervised image
based machine learning step utilising Definiens’ Com-
poser Technology within Tissue Studio®. DAPI, panCK
and D2-40 fluorescence were segmented utilising intensity
and area thresholds and classified into Nuclei, Marker 1
and Marker 2 objects respectively. The image analysis
workspace was then imported into Definiens Developer
XD™ software for more sophisticated hierarchical image
manipulation and object optimisation whilst negating false
positive nuclei and objects. Stromal Marker 1 and Marker
2 objects and their co-localisation were then classified into
tumour bud categories, lymphatic vessels and lymphatic
vessel invasion, respectively, prior to their quantification.
Tumour buds were defined as containing 1–5 cells only
[13,34]; therefore Marker 1 objects must contain 1–5
associated nuclei to be classified as a tumour bud. The
invasive front of the smallest tissue section was captured
in its entirety by 15 images. Therefore only 15 images
from the invasive front of subsequent tissue sections were
used to quantify the histopathological features. The 15 im-
ages containing the highest number of LVI events were
selected and from where LVD and TB counts were
calculated.
Data handling and statistics
Prior to statistical analysis TB and LVI objects, exported
from the 15 images, were totalled while the average LVDper patient, represented as D2-40 percentage of stroma,
was calculated from the 15 images. Post data handling,
LVI, LVD and TB parameters were loaded into X-Tile
(University of Yale) [35] software along with patient out-
come information and optimal cut-offs for each parameter
were calculated. Corrected P-values for the cut-offs were
calculated using cross-validation within Monte Carlo sim-
ulations (n = 1000). Cut-offs, patient data and variables
were uploaded into SPSS software for Cox-regression uni-
variate and multivariable analysis. Pearson’s Correlation
between the histopathological features was also calculated
using the SPSS software and P-values for the correlation
was adjusted by Bonferoni correction for multiple testing.
TMA navigator (http://www.tmanavigator.org/) [36] was
used to plot the Kaplan-Meier curves and the significance
of the separation was calculated via the log-rank (Mantel-
Cox) test while the P-values are false discovery rate (FDR)
corrected using the Benjamini-Hochberg procedure to
account for multiple hypothesis testing.
Results
Image analysis pipeline for the quantification of
histopathological features (Figure 1)
Step 1: Image import and tissue segmentation
Images were imported into Definiens Tissue Studio® image
analysis software in Tagged Image File Format (TIFF)
using the software’s customized import feature which
loads each of the 3 digitally captured image layers and cre-
ates a composite. The software was initially trained to seg-
ment the tissue into 4 distinct regions of interest by
manually marking up areas of ‘stroma’, ‘tumour’, ‘necrosis/
lumen’ and ‘no tissue’ on representative images to create a
training set. The software’s Composer Technology® utilises
image based machine learning, calculated from the train-
ing set, to automatically segment the ROIs on all subse-
quent images. The analysis rule set was programmed to
only classify consequent objects within the stroma.
Step 2: Object segmentation
The algorithm next segmented the nuclei using DAPI in-
tensity and morphometrics. PanCK and D2-40 fluores-
cence is segmented and classified as Marker 1 and Marker
2 objects respectively. Due to inter-patient marker fluores-
cence heterogeneity each tissue section was assessed for
Figure 1 (See legend on next page.)
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Figure 1 Image analysis pipeline for histopathological feature quantification. A) Images for each wavelength are acquired and digitised
prior to being imported into Definiens Tissue Studio®. B) A Composite image is created within the software; green (panCK), red (D2-40) & blue
(DAPI). C) 1. Tissue level segmentation: Tissue is segmented prior to image based machine learning through Definiens Composer technology;
blue (stroma), maroon (tumour), mustard (lumen/necrosis). C) 2. Object level segmentation: PanCK (Marker 1: red) and D2-40 (Marker 2: green)
staining above set thresholds are segmented. C) 3. Nucleus level segmentation: DAPI channel is used to segment nuclei (yellow). D) Analysis
workspace is imported into Defineins Developer™ for hierarchical layer manipulation and false positive marker identification. E) Object classification
and colocalisation optimisation. 1. Markers 1 in stroma (blue) classified as tumour bud (red; 1–5 nuclei), bud with debris nucleus (light blue;
debris nuclei associated), irrelevant marker (pink; no associated nucleus) and large bud (dark blue; >5 nuclei). 2. Lymphatic vessels and lumen
are segmented and classified (green). 3. Colocalisation of tumour buds and lymphatic vessels are classified (yellow; LVI), (pink; vessel border to LVI).
F. Relevant objects are quantified and exported from the software; Figure 1F is representative of example data acquired from image object
analysis. G. Prognostic results are calculated from the exported analysis data which was acquired from image object quantification.
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segmentation of epithelial cells and lymphatic vessels.
Step 3: Object optimisation
After initial object segmentation has been carried out
in Tissue Studio® the Definiens workspace is imported
into the Developer XD™ software package where false
nuclei and objects are negated dependent on area, in-
tensity and texture. Nuclear objects which are under
16 μm2 are re-classified as debris nuclei. Due to the
phenomenon of non-specific staining at the edge of
tissue through immunohistochemistry both positive
Marker 1 and 2 objects within 50 μm of ‘no tissue’ are
classified as edge effect (Additional file 1: Figure S1).
Remaining neighbouring Markers 1 (panCK), in the
stroma ROI alone, are merged and optimised for accur-
ate epithelial segmentation and are hierarchically clas-
sified as ‘irrelevant marker’ (no associated nuclei), ‘bud
with debris nucleus’ (only debris nuclei associated with
marker), ‘tumour bud’ (1–5 associated nuclei) and
‘large bud’ (over 5 nuclei associated). Neighbouring
Markers 2 (D2-40), in the stroma, are also merged,
while the vessel lumen is combined with the vessel
wall, resulting in objects classified as vessels. Finally
the co-localisation of tumour buds and vessels are clas-
sified as LVI. The number of all objects, their colocali-
sation and the vessel percentage of stroma (LVD) are
quantified and exported to assess their prognostic rele-
vance in stratifying CRC patients into high and low risk
subpopulations.
Clinicopathological and Cox-regression analysis
Cut-offs were calculated from the Dukes A-C cohort for
high and low sub-groups and their significance established
by Monte Carlo simulations for LVI (cut-off = 16 LVI
events across 15 images, p <0.0001), LVD (cut-off = 0.7
vessel percentage of stroma averaged across 15 images,
p = 0.002) and TB (cut-off = 287 tumour buds across 15
images, p = 0.0001). The cut-offs established in this
manner were then applied to stratify the Dukes Bsubpopulation. Clinicopathological data and regression
analysis is summarised in Table 1. Univariate analysis
showed TB (HR =5.7; 95% CI, 2.38-13.8), LVI (HR =9.9;
95% CI, 3.57-27.98) and LVD (HR =5.1; 95% CI, 2.04-
12.99) to be significant predictors of survival within the
cohort. In multivariable cox-regression analysis the pre-
dictive model was adjusted for T stage, N stage, Dukes
stage, TB, LVI and LVD and showed that only depth of
local invasion (T stage, HR = 5.22; 95% CI,1.77-15.44)
and LVI (HR =6.08; 95% CI, 1.17-31.41) were independ-
ent predictors of survival. To assess if LVD and LVI
were associated we performed Pearson’s correlation and
found them to be significantly correlated (r = 0.71, p
<0.0003). Similarly LVI and TB were also found to be sig-
nificantly correlated (r = 0.69, p <0.0003) (Figure 2).
Kaplan-Meier survival curves for tumour budding
KM curves were plotted using TMA Navigator to assess
the prognostic relevance of tumour budding in the
Dukes A to C population as well as across the Dukes B
subpopulation alone (Figure 3). Tumour budding was
significantly prognostic for poor outcome and shorter
disease specific survival times in both the full Dukes A-C
cohort (p <0.0001) and within the Dukes B (p = 0.0005)
subpopulation. The percentage of patients still alive at the
end of the study and in the above cut-off subgroup (>than
287 buds) was 7.7% compared to 76% in the low budding
subgroup for the Dukes A-C cohort and 10% compared
to 73% in the Dukes B subpopulation. Tumour budding
was also found to be significant when stratifying high
and low risk patients in 5 year survival rates for the full
Dukes A-C cohort (p < 0.0001 ) and the Dukes B sub-
population (p = 0.0001 ). Automated analysis allows the
quick comparison of the size of the tumour bud to the
significance of prognosis (Additional file 2: Figure S2).
The study showed there was no difference on the pro-
portion of patients alive after full follow up in above cut-
off groups when quantifying TB with 1–2, 1–5 or >5 asso-
ciated nuclei or when summing tumour buds (1–5 nuclei)
and large buds (>5 associated nuclei) within the Dukes B
Figure 2 Correlation of histopathological features. Continuous data plotted through Pearson’s Correlation (r value) after Bonferoni correction
to assess correlation between A) LVI and LVD and B) LVI and TB. Significance shown by P value.
Figure 3 Kaplan-Meier curves for tumour budding. Kaplan-Meier curves showing full follow up disease specific and 5 year disease specific
survival of above cut-off TB group (>287 buds, group 2) and below cut-off TB group (<287 buds, group 1) within the full Dukes A-C cohort and
the Dukes B subpopulation and across disease specific survival or 5 year survival. Significance shown by P value calculated from mantel-cox
analysis and FDR corrected.
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egories of tumour buds within the full cohort also
showed low percentages of patients in all categories
(Table 2).
Kaplan-Meier survival curves for lymphatic vessel density
The LVD was calculated for each image, meaned across
15 images captured per patient and KM curves were
plotted from the results (Figure 4). LVD was significantly
associated with poor outcome and shorter disease specific
survival in both Dukes A-C (p = 0.0001) cohort and the
Dukes B subpopulation (p = 0.0001). Only 26% of patients
within the Dukes A-C cohort and 11% within the Dukes B
subpopulation, who were within the above-cut-off LVD
(>0.7% vessel density) group, survived full follow up. All 8
Dukes C patients were within the high LVD subgroup.
Higher LVD was also significantly associated with poor
disease specific 5 year survival times for both the full co-
hort (p < 0.0001) and the Dukes B subgroup (p = 0.0003).
Kaplan-Meier survival curves for lymphatic vessel invasion
Co-localisation of tumour buds and lymphatic vessels
was categorised as LVI. KM analysis was performed and
LVI was shown to be the most significantly prognostic
parameter associated with shorter survival times in both
the Dukes A-C cohort (p <0.0001) and the Dukes B sub-
population (p <0.0001) (Figure 5). In fact, no patients
survived full follow up within the above cut-off LVI
group (>16 LVI events) in the Dukes B patient subpopu-
lation and only 11% survived follow up within the full
cohort. Similarly to the other histopathological features
quantified, LVI was associated with poor 5 year survival
times for the full cohort (p < 0.0001) and the Dukes B
subpopulation (p < 0.0001).
Discussion
We report a novel semi-automated methodology to reli-
ably identify and quantify three prognostic histopatho-
logical features; LVI, LVD and TB, across the invasive
front of colorectal carcinoma. The features are captured
and exported from a single tissue section using the one
continuous image analysis algorithm. This saves consider-
able resource, compared to serial sectioning and staining
prior to manual semi-quantification of each histopatho-
logical feature, making the approach amenable to a time-
dependent clinical setting. All three histopathologicalTable 2 Number of patients alive after full follow up in high c
Patient cohort P
Tumour buds (1–5 nuc) Small Buds
Dukes A-C cohort n = 1 (7%) n =1
Dukes B subpopulation n = 1 (10%) n = 1
The proportion of patients, after the study was complete, who were alive within the
budding indicates the sum total of the objects within the tumour buds and large bfeatures were found to be significant in predicting poor
outcome and were associated with shorter survival while
LVI was found to be independently prognostic. This may
allow further stratification of a subgroup of Dukes B
patients into low and high risk of poor outcome.
Ueno and Hase et al. [13,34] proposed the definition
of a tumour bud as 1–5 undifferentiated cancer cells
disseminated from the invasive edge. The majority of re-
searchers in the field have adopted this cut-off for TB
size, and have shown TB to be prognostically significant.
However there is no formally agreed quantification
methodology [12,15] resulting in variability in reporting
[23]. As a result TB scoring has not been incorporated
into the core minimal dataset and is not routinely re-
ported in the NHS clinic [1]. TB quantification method-
ology with higher inter-observer concordance has been
proposed by Horcic et al. [24] where TB is manually
counted within 10 fields at x40 objective at the invasive
front. Our automated methodology allows the quantifi-
cation of TB at x20 objective across 15 fields captured
at the invasive front. The 15 images used for automated
TB quantification results in a larger sampling area than
other studies have so far utilised [15]. Although sampling
methodology for the quantification of TB differs, the def-
inition of a tumour bud comprising only 1–5 cells remains
a constant in the literature [15]. The image analysis algo-
rithm developed for this study exports the number of nu-
clei associated with each tumour bud. This allows the
researcher to quickly assess the impact which changing
the TB size criterion has on prognosis. We show that
quantifying tumour buds comprised of only 1–2 cells,
tumour buds comprised of 1–5 cells and tumour buds lar-
ger than 5 cells are all individually associated with poor
outcome and that the classical definition of a tumour bud
is therefore a sound one.
Both blood and lymphatic vessel invasion are associ-
ated with nodal metastasis and poor prognosis [7]. Blood
and lymphatic vascular invasion are, however, under-
recognised in H&E staining alone [26,27]. Therefore the
use of specific histochemical markers, such as Elastica
staining have been employed to highlight blood vessels
and increase reporting rates of invasion events [26]. LVI
is difficult to confidently recognise in H&E stained CRC
tissue sections. This is due to the lack of a surrounding
rim of muscle, such as is found with blood vessels, and
confusion of lymphatic vessels with retraction artefact.ut-off groups within tumour bud size categories
atients alive post follow up
(1–2 nuc) Large buds (>5nuc) Total tumour budding
(7%) n = 4 (23%) n =2 (14%)
(10%) n = 1 (10%) n = 1 (10%)
high-cut off groups of differing sizes of tumour bud categories. Total tumour
uds categories.
Figure 4 Kaplan-Meier curves for Lymphatic vessel density. Kaplan-Meier curves showing full follow up disease specific and 5 year disease
specific survival of above cut-off LVD group (>0.7% vessels of total stroma area, group 2) and below cut-off LVD group (<0.7 vessel% of stroma
area, group 1) within the full Dukes A-C cohort and the Dukes B subpopulation and across disease specific survival or 5 year survival. Significance
shown by P value calculated from mantel-cox analysis and FDR corrected.
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is another contributing factor for the absence of lymphatic
vascular based prognostic features from the minimal core
data set and so standard practice is to not report LVI or
LVD in the clinic. To overcome the problem of identifying
LVI, studies have employed immunohistochemical staining
with a D2-40 antibody which specifically binds to
lymphatic vessel endothelial cells [22,28]. Dual staining
of epithelium and vessels allows easier recognition and
reporting of LVI events [28] within the complex tumour
microenvironment while automated quantification adds
further robustness to the data. LVI alone has been asso-
ciated with lymph node metastasis (LNM) and poor
outcome [22,29]. The under-recognition of LVI may be
a contributing factor for the under-staging of CRC pa-
tients [22,27] and disease recurrence in ~30% of the
Dukes B population [4,37]. Our methodology quantifies
tumour buds invading small lymphatic vessels which we
term as LVI. We observe that out of all the histopatho-
logical features we measured, LVI is the most significantlyprognostic. KM analysis shows that no Dukes B patients
with above cut-off LVI survived follow up. LVI was also
the only parameter to independently be associated with an
adverse effect on disease specific survival. Some studies
have shown LVD to be prognostic and associated to poor
outcome or LNM [8,38] however others show that no cor-
relation exists [9,39]. LVD assessment is, however, not
standardised and most researchers employ various magni-
fications and numbers of LVD “hot-spots” utilised to cre-
ate a mean LVD while observer variability has been shown
to be strong [9]. Bias is therefore introduced to these stud-
ies which can be negated by WSI and automated image
analysis of the invasive front or entire tissue section. In
the methodology, which we demonstrate here, we auto-
matically segment the stroma from the tumour and by
doing so we are able to calculate the LVD only within the
stromal compartment. The methodology does not rely on
the manual locating of LVD hot-spots; rather the quantifi-
cation of LVD across 15 images taken from the invasive
front which contained the highest LVI events is used. By
Figure 5 Kaplan-Meier curves for lymphatic vessel invasion. Kaplan-Meier curves showing full follow up disease specific and 5 year disease
specific survival of above cut-off LVI group (>16 LVI events, group 2) and below cut-off LVD group (<16 LVI events, group 1) within the full Dukes
A-C cohort or the Dukes B subpopulation and across disease specific survival or 5 year survival. Significance shown by P value calculated from
mantel-cox analysis and FDR corrected.
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bias we have shown LVD to be significantly associated to
poor outcome (p = 0.0001). All Dukes C patients had a
high category of LVD which suggests that lymphangiogen-
esis may occur as the disease progresses.
It is unknown whether lymphangiogenesis occurs due
to a host reaction attacking the tumour or by tumour
cell signalling, however we show that LVI is correlated
to LVD (r = 0.71, p < 0.0003) which is in accord with separ-
ate studies [40,41]. We also observed that LVI is associated
with TB (<0.0003), as did Ohtsuki et al. [28]. TBs could be
suggested to be a more invasive subpopulation of cells
disseminated from the tumour mass and if so may have
acquired the ability to invade the lymphatic system and
metastasise to distant nodes.
The automatic quantification of prognostic histopatho-
logical features lends further proof to the value of report-
ing TB, LVI and LVD to stratify high risk CRC patients.
The methodology is amenable to standardisation betweeninstitutions allowing consistent reporting of CRC. TB, LVI
and LVD were all more significantly associated with poor
outcome than Dukes staging, when performing univariate
regression analysis, within this proof of methodology
study. The image analysis quantification methodology of
these three histopathological features, upon further valid-
ation in large and disparate cohorts, may become more
widely accepted as standardised prognostic factors amen-
able to being incorporated into the minimal core data set
and TNM staging.
The ability to quantify prognostically relevant histo-
pathological features, in a robust and routine manner
through automated image analysis, will not only standard-
ise the practice and negate observer variability but will free
up a pathologist’s valuable time. We believe that as digital
pathology becomes more common place within the clinic,
automated quantification of histopathological features, as
demonstrated here, will become an invaluable tool in the
pathologist’s repertoire to stratify high risk cancer patients.
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In conclusion, we demonstrate a computer based image
analysis methodology to quantify tumour buds, lymphatic
vessel density and lymphatic vessel invasion in immuno-
fluorescently labelled colorectal cancer tissue sections.
This methodology has the means to standardise the quan-
tification of the three histopathological features in a robust
fashion. We applied the methodology to a colorectal can-
cer cohort consisting of patients spanning Dukes A –C
diagnoses and found all the histopathological features to
be significantly relevant to prognosis. Lymphatic vessel
invasion, in our study, was shown to be an independent
predictor of survival.
Additional files
Additional file 1: Figure S1. Classification of false nuclei and objects.
Original composite images are pseudocoloured blue (DAPI), green
(panCK) and red (D2-40). Images for the DAPI channel alone are
greyscale. A)1. False nuclei are classified and negated as are nuclear
debris. To negate a false nuclei count, post-segmentation, in the stroma
or within tumour buds, nuclei under 16 μm2 are classified as debris
nuclei. A white arrow shows a small section from a stromal nucleus being
segmented by the tumour bud and classified as debris nucleus. A high
background intensity of DAPI, increased by a segmented section of a
stromal nucleus within the tumour bud, has created a false nucleus (pink).
This is classified as such and negated. A)2. The tissue section in the
example has high auto-fluorescence within the DAPI channel, the false
nuclei segmented as a result of this are classified as such (pink). A)3. High
DAPI channel auto-fluorescence of goblet cells within colonic crypts
result in false nuclei segmentation, these are too classified as such (pink).
B) Auto-fluorescence of muscle cells, within the Cy3 channel, may lead to
their segmentation as panCk positive epithelial cells. Intensity and texture
parameters are utilised to classify the falsely segmented objects as
‘non-specific CK’. C) Non-specific staining of both panCk and D2-40
antibodies occurs close to the edge of tissue. All positively segmented
objects which are 50 μm from ‘no tissue’ (green) are classified as ‘edge
effect’ (blue).
Additional file 2: Figure S2. Kaplan-Meier plots comparing prognostic
significance of quantifying differing sizes of tumour bud. A) Kaplan-Meier
curve showing disease specific survival times for below cut-off (group 1)
and above cut-off (group 2) in tumour buds with 1–5 nuclei associated.
B) Kaplan-Meier curve showing disease specific survival times for below
cut-off (group 1) and above cut-off (group 2)in tumour buds with 1–2
nuclei associated. C) Kaplan-Meier curve showing disease specific survival
times for below cut-off (group 1) and above cut-off (group 2) in tumour
buds with greater than 5 nuclei associated. D) Kaplan-Meier curve
showing disease specific survival times for below cut-off (group 1) and
above cut-off (group 2) upon the summing of tumour buds with 1–5
nuclei and tumour buds with greater than 5 nuclei.
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